Barclays upgraded shares of Edwards Lifesciences (NYSE:EW – Free Report) to a strong-buy rating in a research note issued to investors on Wednesday,Zacks reports.
Several other equities analysts also recently commented on the stock. Piper Sandler reissued an “overweight” rating and issued a $101.00 price objective (up from $100.00) on shares of Edwards Lifesciences in a research note on Friday, July 24th. Evercore reissued an “outperform” rating and issued a $100.00 price target on shares of Edwards Lifesciences in a research note on Monday, July 6th. BTIG Research reaffirmed a “buy” rating and issued a $110.00 price objective on shares of Edwards Lifesciences in a research note on Friday, September 11th. Wall Street Zen cut Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Saturday, September 26th. Finally, Leerink Partners raised shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and upped their price target for the company from $87.00 to $101.00 in a research report on Friday, July 24th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $100.27.
Read Our Latest Stock Analysis on Edwards Lifesciences
Edwards Lifesciences Trading Down 1.0%
Edwards Lifesciences (NYSE:EW – Get Free Report) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The business had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. During the same quarter last year, the business posted $0.67 EPS. The firm’s revenue for the quarter was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Analysts predict that Edwards Lifesciences will post 3 EPS for the current fiscal year.
Insider Transactions at Edwards Lifesciences
In related news, VP Annette Brüls sold 2,644 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $89.98, for a total transaction of $237,907.12. Following the transaction, the vice president owned 17,984 shares of the company’s stock, valued at $1,618,200.32. The trade was a 12.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Andrew M. Dahl sold 544 shares of the company’s stock in a transaction on Monday, August 31st. The stock was sold at an average price of $91.06, for a total value of $49,536.64. Following the sale, the senior vice president owned 14,868 shares of the company’s stock, valued at $1,353,880.08. This trade represents a 3.53% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 5,045 shares of company stock valued at $455,341 over the last three months. Corporate insiders own 0.31% of the company’s stock.
Institutional Investors Weigh In On Edwards Lifesciences
Several large investors have recently made changes to their positions in EW. Hanson & Doremus Investment Management bought a new stake in shares of Edwards Lifesciences in the 1st quarter worth approximately $25,000. MV Capital Management Inc. purchased a new stake in Edwards Lifesciences during the 4th quarter worth about $26,000. RMG Wealth Management LLC purchased a new stake in Edwards Lifesciences during the 1st quarter worth about $26,000. Pin Oak Investment Advisors Inc. bought a new position in Edwards Lifesciences in the 2nd quarter worth about $26,000. Finally, TrinityBridge Ltd bought a new position in shares of Edwards Lifesciences in the second quarter valued at approximately $27,000. 79.46% of the stock is owned by hedge funds and other institutional investors.
About Edwards Lifesciences
Edwards Lifesciences Corporation is a medical technology company focused on therapies for structural heart disease and other cardiovascular conditions. The company develops and manufactures heart valve replacement and repair technologies, including transcatheter aortic valve replacement systems, surgical heart valves, transcatheter mitral and tricuspid therapies, and related delivery systems and accessories.
Founded in 1958 by engineer Miles “Lowell” Edwards, the company helped pioneer artificial heart valves and has played a significant role in the development of transcatheter valve replacement.
Featured Stories
- Five stocks we like better than Edwards Lifesciences
- Skydance Just Became a Media Giant—With an $80 Billion Debt Load
- Could Velo3D Be the Next Defense Buyout Target?
- Penguin Solutions Is Soaring as AI Memory Demand Explodes
- Alphabet’s Chart Is Coiling—and the Fundamentals May Be Ready to Back It Up
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
